Radius Ventures

EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers products such as EsophyX, which enables transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions provides SerosaFuse Fasteners, a non-resorbable polypropylene material with strength comparable to traditional sutures. Beyond its product offerings, the company supports healthcare professionals through trainer-led courses and various consultative services, including pre-authorization and medical review. Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, EndoGastric Solutions was previously known as EsophyX, Inc. before its rebranding in January 2005.

EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers products such as EsophyX, which enables transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions provides SerosaFuse Fasteners, a non-resorbable polypropylene material with strength comparable to traditional sutures. Beyond its product offerings, the company supports healthcare professionals through trainer-led courses and various consultative services, including pre-authorization and medical review. Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, EndoGastric Solutions was previously known as EsophyX, Inc. before its rebranding in January 2005.

MID has developed the FloShield system, a franchise of products that substantially improve visualization during laparoscopic surgery. During laparoscopic surgery, it is common for condensation to form on the end of the laparoscope obscuring vision. It is also common for debris from the ultrasonic scalpel, cautery, or even blood products themselves to degrade the surgical view. Most commonly, surgeons will need to remove the laparoscope for manual cleaning. It was founded in 2006 and headquartered in Columbus, Ohio.

Healthsense, Inc. is a provider of remote monitoring solutions specifically designed for the senior care continuum. Founded in 2001 and based in Mendota Heights, Minnesota, the company specializes in health and safety monitoring systems that track essential daily activities such as eating, sleeping, toileting, and movement. Healthsense's technology includes analytics that transform data into actionable insights, a centralized dashboard, health notes that alert caregivers to behavioral changes, and real-time notifications for urgent needs. These solutions are aimed at enhancing the quality of care in senior living, managed care, and home care settings, ultimately promoting greater independence and improved experiences for seniors. As of late 2016, Healthsense operates as a subsidiary of GreatCall, Inc.

MID has developed the FloShield system, a franchise of products that substantially improve visualization during laparoscopic surgery. During laparoscopic surgery, it is common for condensation to form on the end of the laparoscope obscuring vision. It is also common for debris from the ultrasonic scalpel, cautery, or even blood products themselves to degrade the surgical view. Most commonly, surgeons will need to remove the laparoscope for manual cleaning. It was founded in 2006 and headquartered in Columbus, Ohio.

Impliant Ltd. and over $50 million have been invested in laboratory testing and clinical work to perfect the implant, the instrumentation, and the surgical technique. The TOPS(TM) System aims to revolutionize the spinal implant market in much the same way that total hip and total knee replacement systems displaced hip and knee fusions. Premia Spine's singular focus today is to provide patients and surgeons with a clinically-proven superior solution to lumbar fusion surgery.

EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers products such as EsophyX, which enables transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions provides SerosaFuse Fasteners, a non-resorbable polypropylene material with strength comparable to traditional sutures. Beyond its product offerings, the company supports healthcare professionals through trainer-led courses and various consultative services, including pre-authorization and medical review. Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, EndoGastric Solutions was previously known as EsophyX, Inc. before its rebranding in January 2005.

Tabula Rasa Healthcare, formerly known as CareKinesis, specializes in state-of-the-art medication management solutions that leverage technology, science, and services to enhance the quality of care, reduce costs, and mitigate risks associated with ineffective medication plans. Their innovative approach aims to optimize medication therapy for improved patient outcomes.

MID has developed the FloShield system, a franchise of products that substantially improve visualization during laparoscopic surgery. During laparoscopic surgery, it is common for condensation to form on the end of the laparoscope obscuring vision. It is also common for debris from the ultrasonic scalpel, cautery, or even blood products themselves to degrade the surgical view. Most commonly, surgeons will need to remove the laparoscope for manual cleaning. It was founded in 2006 and headquartered in Columbus, Ohio.

Healthsense, Inc. is a provider of remote monitoring solutions specifically designed for the senior care continuum. Founded in 2001 and based in Mendota Heights, Minnesota, the company specializes in health and safety monitoring systems that track essential daily activities such as eating, sleeping, toileting, and movement. Healthsense's technology includes analytics that transform data into actionable insights, a centralized dashboard, health notes that alert caregivers to behavioral changes, and real-time notifications for urgent needs. These solutions are aimed at enhancing the quality of care in senior living, managed care, and home care settings, ultimately promoting greater independence and improved experiences for seniors. As of late 2016, Healthsense operates as a subsidiary of GreatCall, Inc.

Ambit Biosciences is a privately-held biopharmaceutical company that specializes in the discovery and development of small molecule kinase inhibitors aimed at treating cancer and inflammatory diseases. The company's lead compound, AC220, is a selective and orally bioavailable inhibitor of FMS-like tyrosine kinase-3 (FLT3), currently undergoing clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML). Ambit is collaborating with Astellas Pharma Inc. to jointly develop and commercialize FLT3 kinase inhibitors across various therapeutic areas. In addition to AC220, Ambit's clinical pipeline features AC480, a pan-HER inhibitor, and AC430, an oral inhibitor of JAK2. Furthermore, the company has several preclinical candidates, including CEP-32496, a BRAF inhibitor that is licensed to Cephalon. Through its innovative approach, Ambit aims to enhance treatment outcomes for cancer patients.

Tactile Systems Technology, Inc. is a medical technology company based in Minneapolis, Minnesota, focused on developing and providing innovative medical devices for chronic diseases. The company specializes in products designed to improve the management of conditions such as lymphedema and chronic venous insufficiency. Among its offerings is the Flexitouch Plus system, a pneumatic compression device for lymphedema treatment, and the Entré System, a portable device for at-home treatment of venous disorders. Additionally, Tactile Medical provides the ACTitouch system for managing chronic venous insufficiency and the Airwear Gradient Compression Wrap, marketed as Aero-Wrap, which aids in managing venous issues and lymphedema. Established in 1995, Tactile Systems aims to enhance patient care and promote effective home treatment solutions for these chronic conditions.

Healthsense, Inc. is a provider of remote monitoring solutions specifically designed for the senior care continuum. Founded in 2001 and based in Mendota Heights, Minnesota, the company specializes in health and safety monitoring systems that track essential daily activities such as eating, sleeping, toileting, and movement. Healthsense's technology includes analytics that transform data into actionable insights, a centralized dashboard, health notes that alert caregivers to behavioral changes, and real-time notifications for urgent needs. These solutions are aimed at enhancing the quality of care in senior living, managed care, and home care settings, ultimately promoting greater independence and improved experiences for seniors. As of late 2016, Healthsense operates as a subsidiary of GreatCall, Inc.

EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers products such as EsophyX, which enables transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions provides SerosaFuse Fasteners, a non-resorbable polypropylene material with strength comparable to traditional sutures. Beyond its product offerings, the company supports healthcare professionals through trainer-led courses and various consultative services, including pre-authorization and medical review. Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, EndoGastric Solutions was previously known as EsophyX, Inc. before its rebranding in January 2005.

EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers products such as EsophyX, which enables transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions provides SerosaFuse Fasteners, a non-resorbable polypropylene material with strength comparable to traditional sutures. Beyond its product offerings, the company supports healthcare professionals through trainer-led courses and various consultative services, including pre-authorization and medical review. Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, EndoGastric Solutions was previously known as EsophyX, Inc. before its rebranding in January 2005.

EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers products such as EsophyX, which enables transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions provides SerosaFuse Fasteners, a non-resorbable polypropylene material with strength comparable to traditional sutures. Beyond its product offerings, the company supports healthcare professionals through trainer-led courses and various consultative services, including pre-authorization and medical review. Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, EndoGastric Solutions was previously known as EsophyX, Inc. before its rebranding in January 2005.

Ambit Biosciences is a privately-held biopharmaceutical company that specializes in the discovery and development of small molecule kinase inhibitors aimed at treating cancer and inflammatory diseases. The company's lead compound, AC220, is a selective and orally bioavailable inhibitor of FMS-like tyrosine kinase-3 (FLT3), currently undergoing clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML). Ambit is collaborating with Astellas Pharma Inc. to jointly develop and commercialize FLT3 kinase inhibitors across various therapeutic areas. In addition to AC220, Ambit's clinical pipeline features AC480, a pan-HER inhibitor, and AC430, an oral inhibitor of JAK2. Furthermore, the company has several preclinical candidates, including CEP-32496, a BRAF inhibitor that is licensed to Cephalon. Through its innovative approach, Ambit aims to enhance treatment outcomes for cancer patients.

U-Systems is a developer and manufacturer of advanced ultrasound systems and software specifically designed to assist radiologists in the detection of breast cancer, particularly in women with dense breast tissue. The company’s innovative breast ultrasound systems produce 3D images that enhance visualization of targeted areas of concern within the breast. In addition to its focus on breast cancer diagnostics, U-Systems also designs and manufactures high-quality racking enclosures and cooling products aimed at reducing noise, heat, and costs in data centers and offices, utilizing innovative design principles and state-of-the-art manufacturing processes.

EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers products such as EsophyX, which enables transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions provides SerosaFuse Fasteners, a non-resorbable polypropylene material with strength comparable to traditional sutures. Beyond its product offerings, the company supports healthcare professionals through trainer-led courses and various consultative services, including pre-authorization and medical review. Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, EndoGastric Solutions was previously known as EsophyX, Inc. before its rebranding in January 2005.

Healthsense, Inc. is a provider of remote monitoring solutions specifically designed for the senior care continuum. Founded in 2001 and based in Mendota Heights, Minnesota, the company specializes in health and safety monitoring systems that track essential daily activities such as eating, sleeping, toileting, and movement. Healthsense's technology includes analytics that transform data into actionable insights, a centralized dashboard, health notes that alert caregivers to behavioral changes, and real-time notifications for urgent needs. These solutions are aimed at enhancing the quality of care in senior living, managed care, and home care settings, ultimately promoting greater independence and improved experiences for seniors. As of late 2016, Healthsense operates as a subsidiary of GreatCall, Inc.

Management Health Solutions, Inc. (MHS) is a prominent provider of integrated inventory management solutions tailored for hospitals and healthcare systems in North America. Established in 1999 and headquartered in Fairfield, Connecticut, MHS focuses on reducing clinical supply inventory costs while streamlining supply chain operations. The company enhances patient safety and financial performance through a combination of professional services, content solutions, benchmarks, advanced technology, and mobile device management. By implementing its solutions, MHS helps healthcare organizations achieve measurable returns on investment, ultimately contributing to more efficient and effective clinical supply management.

Heartscape Technologies, Inc. develops and markets medical devices for hospitals in the United States. The company offers PRIME ECG System, a cardiac diagnostic system designed to diagnose heart attacks and ischemia. Its PRIME ECG System displays a range of images that allows a physician to detect potential problem areas and explore important details needed for diagnosis; and various test reports.

Resolvyx Pharmaceuticals is developing an entirely new class of medicines called Resolvins. Resolvins are naturally-occurring, small molecule lipid mediators with the potential to treat a wide range of inflammatory diseases. Unlike most anti-inflammatory drugs which suppress the body's inflammatory response, Resolvins work by activating the body's own mechanisms for shutting off, or resolving, inflammation.

Medingo develops and produces miniature medical devices for people with diabetes. The company's flagship product is the Solo MicroPump, a tiny insulin pump that allows people with diabetes to deliver insulin discreetly without tubing or needles. The company was founded in 2005 and is based in Yoqneam Illit, Israel and the US Corporate Office is in Tampa, FL.

Ambit Biosciences is a privately-held biopharmaceutical company that specializes in the discovery and development of small molecule kinase inhibitors aimed at treating cancer and inflammatory diseases. The company's lead compound, AC220, is a selective and orally bioavailable inhibitor of FMS-like tyrosine kinase-3 (FLT3), currently undergoing clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML). Ambit is collaborating with Astellas Pharma Inc. to jointly develop and commercialize FLT3 kinase inhibitors across various therapeutic areas. In addition to AC220, Ambit's clinical pipeline features AC480, a pan-HER inhibitor, and AC430, an oral inhibitor of JAK2. Furthermore, the company has several preclinical candidates, including CEP-32496, a BRAF inhibitor that is licensed to Cephalon. Through its innovative approach, Ambit aims to enhance treatment outcomes for cancer patients.

U-Systems is a developer and manufacturer of advanced ultrasound systems and software specifically designed to assist radiologists in the detection of breast cancer, particularly in women with dense breast tissue. The company’s innovative breast ultrasound systems produce 3D images that enhance visualization of targeted areas of concern within the breast. In addition to its focus on breast cancer diagnostics, U-Systems also designs and manufactures high-quality racking enclosures and cooling products aimed at reducing noise, heat, and costs in data centers and offices, utilizing innovative design principles and state-of-the-art manufacturing processes.

Athersys, Inc. is a biotechnology company headquartered in Cleveland, Ohio, specializing in regenerative medicine. The company focuses on the research and development of therapeutic products aimed at treating various disease indications, including neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary issues. Its primary product, MultiStem cell therapy, is an allogeneic stem cell treatment currently undergoing Phase III clinical trials for ischemic stroke and Phase II trials for acute myocardial infarction. Additionally, MultiStem has completed Phase I trials concerning certain blood-borne cancers. Athersys is also dedicated to developing therapies for veterinary applications and has established collaboration agreements with Healios K.K. and the University of Minnesota to further advance its MultiStem platform in several disease contexts. The company has engaged in various revenue-generating activities, including corporate collaborations, licensing agreements, and government grants. Founded in 1995, Athersys is committed to addressing unmet medical needs through innovative biopharmaceuticals.

BioStorage Technologies is the premier, global provider of comprehensive sample management solutions for the bioscience industry BioStorage Technologies, Inc. was founded in 2002 and is privately held and headquartered in North America in Indianapolis, Indiana with an additional full-service site in Europe near Frankfurt, Germany. Their mission is to provide their clients with world class, biorepository services, exceeding clients’ expectations of service, value and quality while setting the industry standard for the storage, management & logistics of samples.

Heartscape Technologies, Inc. develops and markets medical devices for hospitals in the United States. The company offers PRIME ECG System, a cardiac diagnostic system designed to diagnose heart attacks and ischemia. Its PRIME ECG System displays a range of images that allows a physician to detect potential problem areas and explore important details needed for diagnosis; and various test reports.

Amicus Therapeutics, Inc. is a biotechnology company dedicated to the discovery, development, and commercialization of therapies for rare and orphan diseases. Founded in 2002 and headquartered in Cranbury, New Jersey, the company focuses on developing innovative treatments, including Galafold, an orally administered pharmacological chaperone for Fabry disease. Amicus is also advancing its pipeline with a Phase 3 clinical study of AT-GAA for Pompe disease. The company's research includes a range of first-in-class small molecules designed to treat lysosomal storage diseases by stabilizing misfolded enzymes in patients. This therapeutic approach potentially enhances the effectiveness of enzyme replacement therapies. Amicus Therapeutics has established collaborations with institutions such as Nationwide Children's Hospital and the University of Pennsylvania to further its research and development efforts.

Heartscape Technologies, Inc. develops and markets medical devices for hospitals in the United States. The company offers PRIME ECG System, a cardiac diagnostic system designed to diagnose heart attacks and ischemia. Its PRIME ECG System displays a range of images that allows a physician to detect potential problem areas and explore important details needed for diagnosis; and various test reports.

Heartscape Technologies, Inc. develops and markets medical devices for hospitals in the United States. The company offers PRIME ECG System, a cardiac diagnostic system designed to diagnose heart attacks and ischemia. Its PRIME ECG System displays a range of images that allows a physician to detect potential problem areas and explore important details needed for diagnosis; and various test reports.

Heartscape Technologies, Inc. develops and markets medical devices for hospitals in the United States. The company offers PRIME ECG System, a cardiac diagnostic system designed to diagnose heart attacks and ischemia. Its PRIME ECG System displays a range of images that allows a physician to detect potential problem areas and explore important details needed for diagnosis; and various test reports.

Heartscape Technologies, Inc. develops and markets medical devices for hospitals in the United States. The company offers PRIME ECG System, a cardiac diagnostic system designed to diagnose heart attacks and ischemia. Its PRIME ECG System displays a range of images that allows a physician to detect potential problem areas and explore important details needed for diagnosis; and various test reports.

Amicus Therapeutics, Inc. is a biotechnology company dedicated to the discovery, development, and commercialization of therapies for rare and orphan diseases. Founded in 2002 and headquartered in Cranbury, New Jersey, the company focuses on developing innovative treatments, including Galafold, an orally administered pharmacological chaperone for Fabry disease. Amicus is also advancing its pipeline with a Phase 3 clinical study of AT-GAA for Pompe disease. The company's research includes a range of first-in-class small molecules designed to treat lysosomal storage diseases by stabilizing misfolded enzymes in patients. This therapeutic approach potentially enhances the effectiveness of enzyme replacement therapies. Amicus Therapeutics has established collaborations with institutions such as Nationwide Children's Hospital and the University of Pennsylvania to further its research and development efforts.

EyeTel Imaging, founded in 1996, specializes in developing advanced imaging technologies aimed at preventing vision loss associated with undetected diabetic retinopathy. The company's flagship product, the EyeTel Retinal Imaging System, utilizes the DigiScope, a semi-automated fundus camera that captures high-quality images, facilitating the detection of various ocular conditions, including age-related macular degeneration and glaucoma. EyeTel also operates the EyeTel Reading Center, a telemedicine service that offers expert analysis of patient images by trained specialists, ensuring accurate diagnoses. Collaborating with the Wilmer Eye Institute and manufacturing partner Topzone in China, EyeTel has successfully enhanced its retinal imaging capabilities while maintaining a commitment to cost-effectiveness and ease of use. The technology is clinically validated and designed for primary care settings, reflecting the company's dedication to improving patient care in a convenient manner.

Amicus Therapeutics, Inc. is a biotechnology company dedicated to the discovery, development, and commercialization of therapies for rare and orphan diseases. Founded in 2002 and headquartered in Cranbury, New Jersey, the company focuses on developing innovative treatments, including Galafold, an orally administered pharmacological chaperone for Fabry disease. Amicus is also advancing its pipeline with a Phase 3 clinical study of AT-GAA for Pompe disease. The company's research includes a range of first-in-class small molecules designed to treat lysosomal storage diseases by stabilizing misfolded enzymes in patients. This therapeutic approach potentially enhances the effectiveness of enzyme replacement therapies. Amicus Therapeutics has established collaborations with institutions such as Nationwide Children's Hospital and the University of Pennsylvania to further its research and development efforts.

Phylogix Inc. is a biotechnology company focused on tissue protection and oncology. The company develops lectin-based drugs focused on tissue protection, oncology, and immunology. It also involves in the development of FRIL, an agent to protect patients from the toxic side-effects of chemotherapy. Phylogix Inc. is based in Scarborough, Maine.

EyeTel Imaging, founded in 1996, specializes in developing advanced imaging technologies aimed at preventing vision loss associated with undetected diabetic retinopathy. The company's flagship product, the EyeTel Retinal Imaging System, utilizes the DigiScope, a semi-automated fundus camera that captures high-quality images, facilitating the detection of various ocular conditions, including age-related macular degeneration and glaucoma. EyeTel also operates the EyeTel Reading Center, a telemedicine service that offers expert analysis of patient images by trained specialists, ensuring accurate diagnoses. Collaborating with the Wilmer Eye Institute and manufacturing partner Topzone in China, EyeTel has successfully enhanced its retinal imaging capabilities while maintaining a commitment to cost-effectiveness and ease of use. The technology is clinically validated and designed for primary care settings, reflecting the company's dedication to improving patient care in a convenient manner.

ZettaCore is at the forefront of molecular electronics, dedicated to creating advanced molecular materials tailored for the electronics industry. By utilizing innovative chemistry, the company enhances existing manufacturing processes, facilitating a shift towards improved performance while simultaneously reducing costs.

NuGEN Technologies, Inc. is a biotechnology company based in San Carlos, California, specializing in next-generation sequencing (NGS) kits and genomic sample preparation reagents. Founded in 2000, NuGEN develops innovative solutions that enable scientists to analyze a wide variety of biological samples, regardless of type, quality, or quantity. The company's extensive portfolio includes products for DNA and RNA sample preparation tailored for research and diagnostic applications, addressing needs in RNA-Seq, targeted resequencing, ChIP-Seq, and Methyl-Seq. NuGEN's technologies facilitate high-throughput applications on leading analytical platforms, ensuring robust and reproducible results that support researchers in predicting disease risk and drug response. Additionally, the company offers technical support, customer services, and resources for scientific publications and commercial service providers. NuGEN serves a global customer base through a network of distributors, operating as a subsidiary of Tecan Group Ltd. since 2018.

Health Language is a company that specializes in enterprise terminology management solutions tailored for healthcare organizations. Founded in 2000 and based in Denver, Colorado, it develops a proprietary middleware application that automates the integration of controlled medical vocabulary and coding standards within healthcare IT applications. The company's offerings include health management software, consulting services, and solutions for content standardization, data normalization, and ICD-10 remediation. Health Language aims to enhance interoperability by providing standardized access to medical terminology, enabling consistent modeling, storing, updating, and distribution of information across hospitals, regions, and countries. Its clientele includes payers, providers, and vendors in the healthcare sector.

ZettaCore is at the forefront of molecular electronics, dedicated to creating advanced molecular materials tailored for the electronics industry. By utilizing innovative chemistry, the company enhances existing manufacturing processes, facilitating a shift towards improved performance while simultaneously reducing costs.

NuGEN Technologies, Inc. is a biotechnology company based in San Carlos, California, specializing in next-generation sequencing (NGS) kits and genomic sample preparation reagents. Founded in 2000, NuGEN develops innovative solutions that enable scientists to analyze a wide variety of biological samples, regardless of type, quality, or quantity. The company's extensive portfolio includes products for DNA and RNA sample preparation tailored for research and diagnostic applications, addressing needs in RNA-Seq, targeted resequencing, ChIP-Seq, and Methyl-Seq. NuGEN's technologies facilitate high-throughput applications on leading analytical platforms, ensuring robust and reproducible results that support researchers in predicting disease risk and drug response. Additionally, the company offers technical support, customer services, and resources for scientific publications and commercial service providers. NuGEN serves a global customer base through a network of distributors, operating as a subsidiary of Tecan Group Ltd. since 2018.

TheScientificWorld is a scientific information portal established in 1997 and based in New York. It offers an integrated suite of resources designed to support scientists in their research and professional activities. The platform serves as a comprehensive hub for scientific information, facilitating access to various tools and resources that enhance the research experience for its users.

AMICAS, Inc. provides radiology, and medical image and information management solutions in the United States. Its AMICAS One Suite products provide an end-to-end IT solution for imaging centers, ambulatory care facilities, radiology practices, and billing services. The company offers AMICAS PACS, a Web-based picture archiving and communications system to capture, store, manipulate, and distribute diagnostic images for radiologists, specialists, referring physicians, patients, and healthcare enterprises; and AMICAS RIS, a Web-based radiology information system to capture radiology orders, detail the patient demographic information, schedule appointments and resources, process transcriptions, and generate reports, as well as to code and prepare billing and reimbursement data. It also provides AMICAS RadStream that offers integrated critical results management capabilities and document the communication of critical results reporting of radiology studies; AMICAS Documents, a module to capture, digitize, and associate paper records with digital information; and AMICAS Financials, which facilitates claims submission, payer follow-up, and other billing and accounts receivable management activities. In addition, the company offers AMICAS Reach, a Web-based tool that integrates the radiology report with key images; AMICAS Dashboards, a Web-based system that provides business intelligence capabilities; and AMICAS EDI offering transaction-based functions. Further, it provides professional and consulting services that assist its clients with a planned transition to a digital enterprise, as well as offers software and hardware support, implementation, training, and electronic data interchange services for patient billing and claims processing. The company was formerly known as VitalWorks Inc. and changed its name to AMICAS, Inc. in January 2005. AMICAS, Inc. was founded in 1989 and is headquartered in Boston, Massachusetts.